TAL Stock Overview
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Taro Pharmaceutical Industries Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$39.40 |
| 52 Week High | US$39.80 |
| 52 Week Low | US$22.00 |
| Beta | 0.61 |
| 1 Month Change | 1.55% |
| 3 Month Change | 2.60% |
| 1 Year Change | 79.09% |
| 3 Year Change | -36.45% |
| 5 Year Change | -59.39% |
| Change since IPO | 5.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| TAL | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.1% | -2.0% |
| 1Y | 79.1% | -31.9% | -0.3% |
Return vs Industry: TAL exceeded the German Pharmaceuticals industry which returned -31.9% over the past year.
Return vs Market: TAL exceeded the German Market which returned -0.3% over the past year.
Price Volatility
| TAL volatility | |
|---|---|
| TAL Average Weekly Movement | 1.8% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: TAL has not had significant price volatility in the past 3 months.
Volatility Over Time: TAL's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1959 | 1,554 | Uday Baldota | www.taro.com |
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic.
Taro Pharmaceutical Industries Ltd. Fundamentals Summary
| TAL fundamental statistics | |
|---|---|
| Market cap | €1.49b |
| Earnings (TTM) | €42.91m |
| Revenue (TTM) | €573.45m |
34.8x
P/E Ratio2.6x
P/S RatioIs TAL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TAL income statement (TTM) | |
|---|---|
| Revenue | US$610.83m |
| Cost of Revenue | US$317.53m |
| Gross Profit | US$293.30m |
| Other Expenses | US$247.60m |
| Earnings | US$45.70m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.22 |
| Gross Margin | 48.02% |
| Net Profit Margin | 7.48% |
| Debt/Equity Ratio | 0% |
How did TAL perform over the long term?
See historical performance and comparison